Latest news for Actinogen Medical (OTC:ATGGF) Stock

Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. Geographically, it operates and derives revenue from Australia. It has developed a product Xanamem.

Actinogen Medical Ltd

Atomera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOM#NASDAQ">ATOM</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 23.81 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $72.000 thousand which missed the analyst consensus estimate of $100.000 thousand by 28.00 percent.

Earnings

Earnings Misses

News

ATOM

Atomera Q2 2024 GAAP EPS $(0.16) Misses $(0.15) Estimate, Sales $72.000K Miss $100.000K Estimate

O-I Glass (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OI#NYSE">OI</a>) reported quarterly earnings of $0.44 per share which met the analyst consensus estimate. The company reported quarterly sales of $1.700 billion which missed the analyst consensus estimate of $1.784 billion by 4.73 percent. This is a 10.05 percent decrease over sales of $1.890 billion the same period last year.

O-I Glass Q2 2024 GAAP EPS $0.44, Inline, Sales $1.700B Miss $1.784B Estimate

Guidance

MDLZ

Mondelēz Expects FY24 Organic Net Revenue Growth To Be At Upper End Of 3% - 5% And High Single-digit Adjusted EPS Growth On Constant Currency Basis

Technology giant Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) reported fourth-quarter financial results after the <a href="https://www.benzinga.com/earnings">market close Tuesday.</a>
Here are the key highlights.
What Happened: Microsoft reported fourth-quarter revenue of $64.7 billion, up 15% year-over-year. The revenue total beat a Street consensus estimate of $64.36 billion, according to data <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent073024&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The company reported earnings per share of $2.95 in the fourth quarter, beating a Street consensus estimate of $2.92.
Intelligent Cloud segment revenue was $28.5 billion, up 19% year-over-year. Within the segment, server products and cloud services revenue was up 21% year-over-year. Azure and other cloud services revenue posted year-over-year growth of 29% in the segment.
The Azure growth missed expectations, according to Reuters, sending Microsoft stock lower in after-hours trading Tuesday.
Revenue in the Productivity and Business Processes segment was $20.3 billion, up 11% year-over-year. Office Commercial products and cloud services revenue in the segment were up 12% year-over-year with Office 365 Commercial revenue growth of 13% year-over-year. Office Consumer products and cloud services revenue was up 3% year-over-year.
The company said Microsoft 365 Consumer subscribers grew to 82.5 million.
LinkedIn revenue was up 10% year-over-year in the fourth quarter.
The company's Dynamics products and clouds services revenue was up 16% year-over-year.
Revenue in the More Personal Computing segment revenue totaled $15.9 billion in the fourth quarter, up 14% year-over-year. The segment was led by Windows revenue, up 7% year-over-year, and Windows Commercial products and cloud services revenue growth of 11% year-over-year. Xbox content and services revenue was up 61% year-over-year in the segment thanks to the net impact of the Activision Blizzard acquisition.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/07/40025343/microsoft-q4-earnings-preview-analyst-says-stock-still-has-yet-to-fully-price-in-next-wave-of-cloud">Microsoft Q4 Earnings Preview: Analyst Says &#8216;Stock Still Has Yet To Fully Price In &#8230; Next Wave Of Cloud And AI Growth&#8217;</a>
"Our strong performance this fiscal year speaks both to our innovation and to the trust customers continue to place in Microsoft," Microsoft CEO Satya Nadella said. 
"As a platform company, we are focused on meeting the mission-critical needs of our customers across our at-scale platforms today, while also ensuring we lead the AI era."
The company said it returned $8.4 billion to shareholders in the fourth quarter via share buybacks and dividends.
Microsoft reported record bookings and Microsoft Cloud quarterly revenue of $36.8 billion, up 21% year-over-year.
For the full fiscal year, Microsoft reported revenue of $245.1 billion, up 16% year-over-year. Full year earnings per share were $11.80, up 22% year-over-year.
What's Next: Microsoft will host a conference call and webcast that can be viewed below. The company said it will provide forward-looking guidance during the conference call.
MSFT Price Action: Microsoft shares are down 6% to $395.02 in after-hours trading Tuesday versus a 52-week trading range of $309.45 to $468.35.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40047547/delta-seeks-damages-from-microsoft-crowdstrike-after-major-system-outage">Delta Seeks Damages From Microsoft, CrowdStrike After Major System Outage</a></li>
</ul>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Microsoft Q4 2024 Earnings Call &#x7C; $MSFT" width="500" height="281" src="https://www.youtube.com/embed/Cb_WyMkkhBQ?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<figcaption class="wp-element-caption"> Photo via Shutterstock.</figcaption></figure>

After-Hours Center

Movers

Tech

Trading Ideas

MSFT

Microsoft Q4 Earnings Highlights: Revenue Beat, EPS Beat, Cloud Revenue Up 21% YoY, 'Ensuring We Lead The AI Era'

UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) reported quarterly earnings of $2.16 per share which beat the analyst consensus estimate of $2.01 by 7.46 percent. The company reported quarterly sales of $390.027 million which beat the analyst consensus estimate of $384.937 million by 1.32 percent. This is a 7.24 percent increase over sales of $363.693 million the same period last year.

Earnings Beats

UMBF

UMB Financial Q2 2024 Adj. EPS $2.16 Beats $2.01 Estimate, Sales $390.027M Beat $384.937M Estimate

Ternium (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TX#NYSE">TX</a>) reported quarterly sales of $4.51 billion which missed the analyst consensus estimate of $4.57 billion by 1.32 percent. This is a 16.61 percent increase over sales of $3.87 billion the same period last year.

Ternium Q2 Sales $4.51B Miss $4.57B Estimate

Ashford Hospitality Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHT#NYSE">AHT</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.13 by 107.69 percent. The company reported quarterly sales of $316.482 million which beat the analyst consensus estimate of $308.900 million by 2.45 percent. This is a 15.77 percent decrease over sales of $375.749 million the same period last year.

Ashford Hospitality Trust Q2 2024 FFO $0.27 Beats $0.13 Estimate, Sales $316.482M Beat $308.900M Estimate

Canadian Pacific Kansas Q2 2024 Adj EPS C$1.05, Sales C$3.600B

DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.45) by 24.44 percent. This is a 30.77 percent decrease over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $1.16 million which missed the analyst consensus estimate of $1.68 million by 30.89 percent. This is a 49.52 percent decrease over sales of $2.30 million the same period last year.

DBVT

DBV Technologies Q2 EPS $(0.34) Beats $(0.45) Estimate, Sales $1.16M Miss $1.68M Estimate

&nbsp;This dividend is payable on October 14, 2024, to shareholders of record as of September 30, 2024.

Dividends

Mondelēz Boosts Quarterly Dividend By 11% From $0.425 To $0.47 Per Share

Benchmark Sees Q3 2024 Revenue $630M-$670M Vs $635M Estimate, Sees Adj. EPS $0.52-$0.58 Vs $0.51 Estimate

<ul>
<li>TX45 is an Fc-relaxin fusion protein being evaluated in patients with Group 2 Pulmonary Hypertension (PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF), a serious condition estimated to affect over 600,000 people in the U.S. alone, currently with no approved therapies &nbsp;</li>
<li>Planned initiation of global, 24-week Phase 2 clinical trial to evaluate TX45 administered subcutaneously in subjects with Group 2 PH due to HFpEF (PH-HFpEF) in the third quarter of 2024, with topline trial results expected in 2026 &nbsp;</li>
<li>Phase 1a topline trial results of TX45 in healthy volunteers are expected to be released this September, with detailed data to be subsequently presented at a scientific meeting &nbsp;</li>
<li>Phase 1b hemodynamic trial evaluating single doses of TX45 in subjects with Group 2 PH-HFpEF continues to enroll as planned, with topline study results expected in mid-2025 &nbsp;</li>
</ul>
WATERTOWN, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ah9gI2fSvR0kOQIKijh3A2neP4cQrkBQtvwv9CwYafR2mfgaDx9GnMFIq1hDdho03VW7_NMktC9lfGo9_14BHFkrjyux2di6a6kh0r5-t9M=">Tectonic Therapeutic, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TX45, an Fc-relaxin fusion protein being evaluated for the treatment of patients with Group 2 PH-HFpEF. TX45 aims to address the physiological abnormalities of PH-HFpEF through its effects on both pulmonary and systemic vasodilation, cardiac diastolic dysfunction and potential remodeling in both the pulmonary vessels and cardiac muscle, which could translate into a clinically meaningful improvement in exercise capacity in these patients.

Biotech

General

TECK

TECX

Tectonic Therapeutic Gets U.S. FDA IND Clearance For Lead Program, TX45

Affirm Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) stock gained after B of A Securities analyst Jason Kupferberg upgraded the stock from Neutral to Buy with a <a target="_blank" href="https://www.benzinga.com/quote/AFRM/analyst-ratings" rel="noreferrer noopener">price target of&nbsp;$36</a>.
Kupferberg noted GAAP profitability may be closer than expected by consensus.
The analyst said the fourth-quarter print and guide could be a positive catalyst, and fiscal 2025 forecasts seem achievable.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/07/39795308/affirm-faces-regulatory-shake-up-with-new-cfpb-rules" rel="noreferrer noopener">Affirm Faces Regulatory Shake-Up with New CFPB Rules</a>
A lower interest rate regime should also support RLTC (revenue minus transaction costs, the most crucial P&amp;L metric), Kupferberg said, who is bullish on new and expanded partnerships, i.e., Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>).
Credit risk continues to be well-controlled, the analyst noted.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/30113505/newplot-1-14.png" alt="" class="wp-image-465342" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/30113505/newplot-1-14.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/30113505/newplot-1-14-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
At its November 2023 investor forum, Affirm Holdings detailed a medium-term profitability framework that Kupferberg noted as achievable given expense prudence year-to-date. In the context of this framework, Kupferberg said the Street is mis-modeling warrant expense and share-based compensation.
As warrant expense and Stock-based compensation (SBC) expense grind lower, the analyst forecasted GAAP profitability to arrive in fiscal 2026 faster than consensus.
Kupferberg flagged the increasing market expectations of three rate cuts in 2024 and four in 2025. A lower interest rate environment would be beneficial to Affirm Holdings&#8217; funding costs and for gain on loan sales.
As per the analyst, Affirm Holdings recently moved its merchants to a 36% annual percentage rate (APR) cap on loans, up from 30% previously, which should remain a tailwind for yields and Gross Merchandise Value (GMV) growth.
Given recent share price underperformance, Kupferberg noted the fourth-quarter print could be a positive catalyst.
Affirm Holdings may communicate a more bullish message on profitability while delivering fourth-quarter upside and guiding fiscal 2025 solidly in line, as per the analyst.
New Apple relationships, further scaling of Affirm Card, and potential geographic expansion of existing large partnerships like Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Shopify Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) should all support fiscal 2025 and 2026 forecasts, Kupferberg added.
The analyst projected fiscal 2024 sales of $2.27 billion, fiscal 2025 sales of $2.75 billion and fiscal 2026 sales of $3.24 billion.
Price Action: AFRM shares closed trading higher by 2.31% at $27.46 on Tuesday.
Photo via Company

Fintech news covering the emerging Financial Technology services sector

Fintech

Price Target

Reiteration

Analyst Ratings

AAPL

AFRM

AMZN

SHOP

Affirm's Growth Boosted by Apple and Amazon Partnerships, Lower Interest Rates: Analyst

Terex Sees FY24 Adj. EPS $7.15-$7.45 Vs $7.02 Estimate

Kite Realty Group Sees FY24 NAREIT FFO From $2.02-$2.08 To $2.04-$2.08

Acadia Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKR#NYSE">AKR</a>) reported quarterly earnings of $0.31 per share which met the analyst consensus estimate. The company reported quarterly sales of $85.626 million which beat the analyst consensus estimate of $72.133 million by 18.71 percent. This is a 2.85 percent decrease over sales of $88.141 million the same period last year.

Acadia Realty Trust Q2 2024 FFO $0.31, Inline, Sales $85.626M Beat $72.133M Estimate

TAMARACK Study Update
MacroGenics completed enrollment of the TAMARACK study in the fourth quarter of 2023, and plans to present at ESMO the study's landmark primary endpoint of 6-month rPFS rate, which represents the proportion of study participants who remain alive and progression-free at 6 months.
In late July 2024, after a review of accumulated study data, MacroGenics agreed with the study's Independent Data Monitoring Committee's (IDMC) recommendation that study treatment should be discontinued for the remaining mCRPC study participants who potentially could have received additional doses. Most of these remaining study participants had already received 8-12 cycles of vobra duo. Participants continue to be monitored for adverse events, disease progression and survival.
"Patient safety is our top priority, and having reached the study's primary endpoint, we decided to discontinue additional dosing for the remaining TAMARACK participants who had not yet completed treatment. We expect to have the data necessary to determine next steps for the vobra duo program later this year and will provide further updates on an investor call following our ESMO presentation," continued Dr. Koenig. "We are committed to fully assessing the potential of vobra duo in mCRPC through rigorous evaluation of the data, including the mature median rPFS and OS. We look forward to completing follow-up for the TAMARACK trial before year-end and presenting final data at a future conference."
The Company expects to have the mature efficacy findings, including median rPFS, later in the second half of 2024 and plans to present the data at a subsequent medical conference. The data to be presented at ESMO will be used to inform how future potential studies could be designed.

MGNX

MacroGenics Provides Vobramitamab Duocarmazine Update, Abstract Of Clinical Data Accepted For Poster Presentation At ESMO Congress 2024 In September; Gives TAMARACK Study Update, Says "Patient Safety Is Our Top Priority, And Having Reached The Study's Primary Endpoint, We Decided To Discontinue Additional Dosing For The Remaining Tamarack Participants Who Had Not Yet Completed Treatment:

Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) reported quarterly earnings of $2.16 per share which beat the analyst consensus estimate of $2.06 by 4.85 percent. The company reported quarterly sales of $1.40 billion which missed the analyst consensus estimate of $1.43 billion by 1.87 percent. This is a 0.22 percent decrease over sales of $1.40 billion the same period last year.

Terex Q2 2024 Adj EPS $2.16 Beats $2.06 Estimate, Sales $1.40B Miss $1.43B Estimate

Kite Realty Gr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.50 by 6 percent. The company reported quarterly sales of $212.434 million which beat the analyst consensus estimate of $207.534 million by 2.36 percent. This is a 1.76 percent increase over sales of $208.759 million the same period last year.

Kite Realty Gr Trust Q2 2024 FFO $0.53 Beats $0.50 Estimate, Sales $212.434M Beat $207.534M Estimate

WIIM

AMD shares are trading higher following better-than-expected Q2 earnings.

Actinogen Medical Limited (AU:ACW) has released an update. Actinogen Medical Limited has announced the application for quotation of new securities ...

Actinogen Medical Applies for New ASX Quotation

Actinogen Medical Limited (AU:ACW) has released an update. Actinogen Medical Limited has held a General Meeting where a key resolution was passed, ...

Actinogen Medical Advances Novel Brain Therapies

Actinogen Medical Limited (AU:ACW) has released an update. Actinogen Medical Limited has announced the application for quotation of new securities,...

Actinogen Medical Expands Shares Quotation

Actinogen Medical Limited (AU:ACW) has released an update. Actinogen Medical Limited has announced the application for the quotation of additional ...

Actinogen Medical Applies for Additional ASX Quotation

Actinogen Medical Limited (AU:ACW) has released an update. Actinogen Medical Limited has announced the application for quotation of 3,841,597 new o...

Actinogen Medical Seeks New Securities Quotation

Actinogen Medical Limited (AU:ACW) has released an update. Actinogen Medical Limited has announced the application for quotation of 660,144 new ord...

Actinogen Medical Seeks Quotation for New Shares

Actinogen Medical Limited (AU:ACW) has released an update. Actinogen Medical has announced positive results from their Xanamem phase 2a biomarker t...

Actinogen Medical's Promising Clinical Trials Progress

Actinogen Medical Limited (AU:ACW) has released an update. Actinogen Medical Limited has applied for the quotation of new securities on the Austral...

Actinogen Medical Expands Market Presence

Actinogen Medical Seeks New ASX Quotation

Actinogen Medical Limited (AU:ACW) has released an update. Actinogen Medical announced that its Chief Medical Officer presented a poster at the Alz...

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Actinogen Medical

News

Latest news for Actinogen Medical (OTC:ATGGF) Stock